I would never presume to speak for Dew, but don't you think it is kind of obvious? There is no indication that there is anything substantive that's wrong with the production methodology, the "test" drug's DIS-approval rests mostly on fairly thin split hairs (i.e. the belief that a non-trivial possibility exists that ATryn administration for at-term women is unmanageable because of (a) poorly-defined protocols and/or (b) some degree of unpredictability in those patients' response to ATryn). Pharming is pursuing essentially the same business model, albeit with other species. Barring the ultra-rapid development and approval for a competing process, the main risks apart from a socio-political backlash are funding and expertise, both of which are enhanced by such a merger.
LSBC was looking to produce proteins using tobacco and it looked promising. They ran out of cash
I am amazed that the stock is holding here. I think when the approval was delayed because the emea hadn't inspected the manufacturing the stock went to under 90 cents.
that was a delay not a disapproval. the only thing that can be holding up the stock is people putting too much value into the appeal or the talk of a merger.
the merger doesn't have to be at higher prices though. The process isn't approved and the new data and review would be like starting from scratch
AI
Market Data 
Markets 
